(Q37113440)

18 August 2017

1 reference

title

Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus (English)

1 reference

18 August 2017

main subject

cardiovascular disease

1 reference

systemic lupus erythematosus

inferred from title

1 reference

Christy Sandborg

1

1 reference

18 August 2017

Stacy P Ardoin

series ordinal

2

1 reference

18 August 2017

Laura Schanberg

series ordinal

3

1 reference

18 August 2017

publication date

18 March 2008

1 reference

Nature Clinical Practice Rheumatology

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

258-265

1 reference

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

Garlic extract therapy in children with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Burden : Writing Group III

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

Making the diagnosis of systemic lupus erythematosus in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Mortality in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

The bimodal mortality pattern of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Patient education on cardiovascular aspects of rheumatoid disease: an unmet need

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Risk factors for coronary artery disease in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Protein, body weight, and cardiovascular health

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

1 reference

7 January 2021

Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Secondary causes of hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Cardiac risk factor awareness and management in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Diet, lipoproteins, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Compendium of physical activities: classification of energy costs of human physical activities

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Management of dyslipidemia in children and adolescents with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Clinical interest of PPARs ligands

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Statins in the treatment of central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Statin treatment in children with familial hypercholesterolemia: the younger, the better

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0789

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0789

1 reference

18 August 2017

1 reference